RxDoctor Payments Data

Gino Sedillo, MD

Cardiovascular Disease · Bradenton, FLNPI 1982680179

Payments from drug & device makers

$153,422in general payments, 2019–2025

Across 1,090 payments — averaging $140.75 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • W. L. Gore & Associates, Inc.$47K
  • Veryan Medical Incorporated$44K
  • Cvrx, Inc.$23K
  • Abbott$18K
  • Medtronic$5K
  • Boston Scientific$4K
  • plus $13K from 29 others
$48,620in research payments, 2019–2025

Across 2 payments — averaging $24,310 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.

  • Veryan Medical Incorporated$49K

What the payments were for

  • Consulting fees$30,70535%
  • Speaking & faculty fees$21,14024%
  • Travel & lodging$2,3693%
  • Food & beverage$32,76238%
  • Education$710%

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$153,422 in reported general payments places this provider in the 90th percentile of 1,740 cardiovascular disease providers in Florida.

See all cardiovascular disease providers in Florida

Medicare billing

Part B allowed, 2024
$1,515,540
Medicare patients
1,115
Services billed
6,015

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
EliquisApixaban76$99,569
XareltoRivaroxaban32$34,562
Repatha SureclickEvolocumab45$29,946
BrilintaTicagrelor25$22,842
Prasugrel Hcl20$8,688
EntrestoSacubitril/Valsartan15$6,570
ClopidogrelClopidogrel Bisulfate583$6,271
Atorvastatin Calcium131$1,694
Nifedipine ErNifedipine42$990
Isosorbide Mononitrate ErIsosorbide Mononitrate50$778
Metoprolol Succinate55$700
Diltiazem 24hr ErDiltiazem Hcl14$682
Rosuvastatin Calcium52$643
Carvedilol64$615
Diltiazem 24hr Er (Cd)Diltiazem Hcl34$560

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
PfizerEliquis$24$99,56976 claims
Johnson & JohnsonXarelto$339$34,56232 claims
AstraZenecaBrilinta$215$22,84225 claims
NovartisEntresto$88$6,57015 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 90th percentile of 1,740 cardiovascular disease providers in Florida.

Other cardiovascular disease in Bradenton

See the full list for Florida

Where these figures come from

Is this you, or does something look wrong? →